“Anastomosis Devices Market Report is set to have rapid growth due the rising surgical procedures along with growing incidence of cardiovascular and gastrointestinal diseases at global, regional and national level, influencing the industry trends in each of the sub-segments from 2019 to 2029”, says Visiongain Report

04 September 2019
Pharma

Visiongain has launched a new pharma report Anastomosis Devices Market Forecast 2019-2029: By Product (Disposable, Reusable), By Application (Cardiovascular Surgery, Gastrointestinal Surgery), By Region, Competitive Landscape, and Segment Forecasts.

The global Anastomosis Devices market is poised for rapid growth between 2019 and 2029. The increase in the number of cardiovascular surgical procedures performed and an increase in the prevalence of chronic diseases, such as gastrointestinal and cardiac disorders, are the main factors driving the global market for anastomotic devices worldwide.

According to the European Commission, about 181,000 bypass anastomoses for heart revascularization procedures were performed in the 25 EU Member States in 2016. Among them, Germany conducted about 51,000 cardiac bypass operations in 2016. This will probably fuel the demand of anastomotic devices in the near future.

Furthermore, rapid technological progress is expected to be a favorable reimbursement scenario for cardiac procedures, including coronary artery bypass grafting (CABG), open heart valve replacement and angioplasty, in regions developed for encourage the adoption of anastomotic devices during the forecast period. However, the complications associated with anastomosis, such as anastomotic leaks, are expected to hamper the global market for anastomotic devices.

Leading companies featured in the report include Medtronic; LivaNova PLC; MAQUET Holding B.V. & Co. KG.; Dextera Surgical Inc.; Vitalitec Internaional Inc.; Synovis Micro Companies Alliance, Inc.; and Ethicon US, LLC.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

Read

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

Read

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

Read

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever